Background {#Sec1}
==========

The prognosis and malignancy of primary lung cancer are affected by histopathological findings \[[@CR1], [@CR2]\]. For resectable non-small cell lung cancers (NSCLCs), preoperative diagnostic imaging is essential for determining the best therapeutic strategy, including the type of surgical procedure \[[@CR3]--[@CR5]\]. In the tumor, nodes, and metastasis (TNM) classification, T descriptors reflect tumor size and locoregional invasiveness. Tumor size can be measured definitively on thin-section computed tomography (CT) with a slice thickness of ≤ 1 mm. However, it is difficult to evaluate microscopic tumor invasiveness, such as pleural involvement, lymphatic permeation, and vascular invasion, even on thin-section CT.

Contrast-enhanced CT has been used in functional imaging to evaluate intratumoral necrosis, vascularity, and fibrosis, which are associated with invasiveness and prognosis \[[@CR6]--[@CR8]\]. A dual-energy CT (DE-CT) technique using two types of tube voltage has enabled quantification of the iodine-related attenuation of iodinated contrast material in the tumor after intravenous injection, without the need for an additional non-contrast CT scan \[[@CR9]--[@CR12]\]. It leads to radiation exposure reduction of a patient in a CT examination. Recently, Baxa et al. reported that iodine uptake at the arterial phase of dual phase contrast DE-CT is a feasible method in assessment of anti-EGFR therapy response for NSCLC \[[@CR13]\]. Aoki et al. reported that iodine uptake at the arterial phase of contrast DE-CT is useful quantitative assessment for predicting lung cancer recurrence after stereotactic body radiotherapy \[[@CR14]\]. That is, tumors with lower iodine uptake for pretreatment evaluation showed a worse prognosis after radiotherapy. These research findings indicate that iodine uptake at the arterial phase on contrast CT may be associated with some sort of tumor histopathology such as angiogenesis and hypoxic cell. Our recent study demonstrated that the three-dimensional iodine-related attenuation (3D-IRA; also known as "iodine volume") of primary lung cancers measured by contrast-enhanced DE-CT was significantly associated with their differentiation grade \[[@CR15]\]. Tumor grade correlates directly with microscopic tumor invasiveness \[[@CR16]--[@CR18]\]. Therefore, we speculated that the 3D-IRA might correlate indirectly with the microscopic invasiveness of small-sized NSCLCs. If that is true, a dual-energy technique would enable preoperative prediction of tumor invasiveness.

In this study, we reviewed preoperative data from contrast CT with dual-energy scanning as well as postoperative histopathological findings of NSCLCs ≤ 3 cm that were surgically resected, and validated the hypothesis that the 3D-IRA of the primary lesion could be a predictive factor for locoregional invasiveness.

Methods {#Sec2}
=======

Patient selection {#Sec3}
-----------------

We reviewed the medical records, post-operative pathological records, and preoperative DE-CT images of patients who underwent surgical lung resection for primary lung cancer at our hospital between April 2014 and March 2015. We limited these patients to those with NSCLCs of ≤ 3 cm in diameter that had been definitively diagnosed by pathological examination after surgical resection. Non-solid types of lung cancer that were invisible on mediastinal window settings for thoracic CT were excluded. Patients who received preoperative chemoradiotherapy were also excluded. We recorded patient characteristics (gender, age, and body weight) from medical records, and tumor characteristics (pathological tumor size, histological type, differentiation grade, lymphatic permeation, vascular invasion, and pleural involvement) from pathological records. Herein, the differentiation grade was classified into the following groups: G1, well-differentiated; G2, moderately-differentiated; and G3, poorly-differentiated. We defined locoregional invasive tumors as tumors that had at least one invasive pathologic finding (lymphatic permeation, vascular invasion, or pleural involvement) and non-invasive tumors as tumors that had no invasive pathologic findings \[[@CR19], [@CR20]\].

CT scan protocol {#Sec4}
----------------

All CT scans were performed with a dual-source CT scanner (SOMATOM Definition Flash; Siemens Healthcare, Tokyo, Japan) in the craniocaudal direction with inspiratory apnea. For vessel enhancement, 96 mL of non-ionic contrast medium (Proscope 300, 300 mgI/mL iopromide, Alfresa Pharma, Osaka, Japan; Optiray 320, 320 mgI/mL ioversol, Tyco Healthcare, Tokyo, Japan; or iopamiron 370, 370 mgI/mL iopamidol, Bayer Healthcare, Tokyo, Japan) were used with flow rates of 4.0 mL/sec. Iopromide was used for patients with body weights \< 40 kg, ioversol was used for patients with body weights 40--59 kg, and Iopamidol was used for patients with body weights ≥ 60 kg. Injections were immediately followed by a saline chaser bolus of 20 mL at the same flow rate using a dual-barrel power injector (Dual Shot GX7; Nemoto Kyorindo, Tokyo, Japan).

In our institution, the dual-phase dynamic CTs were performed routinely to preoperative evaluation of lung cancer. After pre-contrast CT scan, the early phase of thoracic CT has been scanned for preoperative evaluation of pulmonary vessels by 3D-pulmonary angiography. The scan delay was evaluated by an automatic bolus tracking system with a circular ROI localized on the thoracic aorta. Scanning started automatically as the attenuation of the ROI increased 70 HU from baseline (about 20--25 sec. after start of injection). A dual-energy scan system (tube A at a peak voltage of 140 kVp and tube B at a peak voltage of 80 kVp) was used for both scans with collimation, 64 × 0.6 mm; gantry rotation speed, 285 msec. Additionally, the delayed phase of thoraco-abdominal CT has been scanned to evaluate lymph node metastasis and abdominal distant metastasis about 2 min later of contrast medium injection. Data were reconstructed with a slice thickness of 1.0-mm at 1.0-mm increments using iterative reconstruction techniques (SAFIRE, Siemens Healthcare, Tokyo, Japan).

Analysis of dual-energy CT images {#Sec5}
---------------------------------

The 3D-IRA of the primary lesion was measured using the syngo "lung nodules" application accessory software \[[@CR15], [@CR21]\]. The DE-CT technique can create iodine-enhanced images from DE-CT raw data sets of 140kVp and 80kVp, and measure absolute quantification of iodine within the tumors. This application can automatically segment a pulmonary nodule and calculate the mean iodine related attenuation of pulmonary nodules with a three-material decomposition algorithm. A chest radiologist who had 21 years of experience reading thoracic CT scans segmented the primary tumor, measured the maximum diameter as clinical tumor size, and recorded the 3D-IRA.

Additionally, corrected 3D-IRA values to reduce the effect of body weight and iodine concentration of contrast medium, were calculated as follows:$$\documentclass[12pt]{minimal}
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Representative cases of CT and iodine-enhanced images are shown in Figs. [1](#Fig1){ref-type="fig"} and [2](#Fig2){ref-type="fig"}.Fig. 1A 66-year-old female patient. A well-differentiated (G1) adenocarcinoma is observed in the left lower lobe. Lymphatic permeation, vascular invasion, and pleural involvement were all negative. **a** Lung window setting. **b** Mediastinal window setting. **c** Iodine-enhanced image of contrast-enhanced CT. The 3D-IRA is 47 HU, and the corrected 3D-IRA is 8.13Fig. 2A 74-year-old female patient. A poorly-differentiated (G3) adenocarcinoma is observed in the left lingula. Vascular invasion, and pleural involvement were positive. **a** Lung window setting. **b** Mediastinal window setting. **c** Iodine-enhanced image of contrast-enhanced CT. The 3D-IRA is 16 HU, and the corrected 3D-IRA is 2.85

Statistical analysis {#Sec6}
--------------------

First, among the three differentiation grade groups (G1 to G3), possible differences in patient characteristics were compared. Gender, ratio of part-solid nodules to solid nodules, locoregional invasive tumor, and lymph node metastases were compared by chi-square test. The age, body weight, clinical and pathological tumor size, 3D-IRA, and corrected 3D-IRA were compared by single-factor analysis of variance (ANOVA). Second, correlations between tumor characteristics and locoregional invasive tumors were individually evaluated using univariate logistic regression analysis. Third, areas under the curve of receiver operating characteristic (ROC) analysis for diagnosis of locoregional invasive tumor were compared between the 3D-IRAs and the corrected 3D-IRAs. Then, Youden's index was used to determine a cut-off level that would indicate a locoregional invasive tumor. Last, multivariate logistic regression analysis was used for the correlation between locoregional invasive tumor and clinical factors for which the p-value was \< 0.2 by univariate logistic analysis.

Analyses were performed using commercial statistical software: Excel 2010 (Microsoft Corp., Redmond, WA) and SPSS version 23 (IBM Corp., Amonk, NY). A p-value \< 0.05 was considered statistically significant.

Results {#Sec7}
=======

A total of 73 resected pulmonary lesions were reviewed, and 10 lesions were excluded because they were non-solid type (Fig. [3](#Fig3){ref-type="fig"}). Finally, 63 consecutive primary lung cancer lesions from 60 patients were selected for analysis (32 males and 28 females; mean age, 67 years \[range, 39--85 years\]; mean body weight, 58.2 kg \[range, 37--85 kg\]). Of these lesions, 54 were adenocarcinomas, 8 were squamous cell carcinomas, and 1 was adenosquamous carcinoma.Fig. 3Study cohort flow chart. A total of 73 surgically resected pulmonary lesions were scanned preoperatively with DE-CT. After exclusion criteria were applied, 63 primary NSCLCs were included in the present analysis

Table [1](#Tab1){ref-type="table"} compares patient and tumor characteristics among differentiation grade groups. The mean ± standard deviation (SD) of 3D-IRA at the arterial phase was 56.1 ± 22.6 HU in G1 tumors, 48.5 ± 23.9 HU in G2 tumours, and 28.4 ± 15.8 HU in G3 tumours. The 3D-IRA was significantly different among the three differentiation grades (*p* = 0.005). The corrected 3D-IRA was also significantly different among the three differentiation grades (*p* = 0.005). Higher-grade tumors had lower 3D-IRA values. The percentage of locoregional invasiveness and lymph node metastases was significantly higher in high-grade tumors (*p* = 0.044 and *p* = 0.012, respectively). The ratios of female and part-solid type tumors were significantly higher in low-grade tumors (*p* = 0.001, and *p* \<0.001, respectively). For age, body weight, and tumor size (both clinical and pathological), no significant differences were observed among the three groups (*p* = 0.912, *p* = 0.677, *p* = 0.758, and *p* = 0.069, respectively).Table 1Comparison of patient and tumor characteristics among differentiation grade groupsG1G2G3*p*-valueMale/female (n)6/1820/88/30.001Age (years)67 ± 767 ± 768 ± 120.912Body weight (kg)58.0 ± 13.857.3 ± 9.360.8 ± 9.30.677Clinical size (mm)22.4 ± 8.124.1 ± 8.223.3 ± 7.80.758Pathological size (mm)17.7 ± 6.921.2 ± 5.522.0 ± 6.70.069Part-solid/Solid (n)15/94/241/10\<0.0013D-IRA (HU)56.1 ± 22.648.5 ± 23.928.4 ± 15.80.005Corrected 3D-IRA9.05 ± 2.978.01 ± 4.094.81 ± 2.560.005Locoregional invasive tumor (%)2554640.044Lymph node metastases (%)025360.0123D-IRA, three-dimensional iodine related attenuation; cSize, clinical size of tumor on CT; pSize, pathological size of tumor

Table [2](#Tab2){ref-type="table"} shows the association between clinical or pathological factors and locoregional invasive tumor using univariate logistic regression analysis. Among the clinical factors, the 3D-IRA and the corrected 3D-IRA were significantly correlated with locoregional invasive tumors (*p* = 0.002 and *p* \< 0.001, respectively). The gender, clinical tumor size, and internal opacity type of the clinical factors that were indicated as p-value \<0.2 were adopted for subsequent multivariate logistic analysis. Among the pathological factors, the size and differentiation grade were significantly correlated with locoregional invasive tumors (*p* = 0.006 and *p* = 0.017, respectively).Table 2Univariate logistic analysis of clinical and pathological factors for locoregional invasivenessOR (95 % CI)*p*-valueClinical factors Male vs. Female0.416 (0.150--1.155)0.092 Body weight1.008 (0.963--1.054)0.741 Age0.972 (0.914--1.034)0.366 Clinical Size1.061 (0.992--1.136)0.085 Subsolid type vs. Solid type2.683 (0.868--8.295)0.087 3D-IRA0.956 (0.930--0.983)0.002 Corrected 3D-IRA0.721 (0.595--0.873)\<0.001Pathological factors Others as compared to adenocarcinoma1.078 (0.261--4.456)0.918 Pathological size1.139 (1.038--1.251)0.006 Differentiation grade2.521 (1.177--5.398)0.0173D-IRA, three-dimensional iodine related attenuation; CI, confidence interval; OR, odds ratio; cSize, clinical size of tumor on CT; pSize, pathological size of tumor

Figure [4](#Fig4){ref-type="fig"} shows the ROC curves of the 3D-IRA and the corrected 3D-IRA for diagnosis of locoregional invasive tumors. The AUC of the 3D-IRA was 0.776 (95 % confidence interval, 0.658 - 0.894) and that of the corrected 3D-IRA was 0.781 (95 % confidence interval, 0.664--0.899). The AUC of the corrected 3D-IRA was higher than that of the 3D-IRA; however, the difference was not significant (*p* = 0.738). A suitable cutoff value for the corrected 3D-IRA was estimated to be 5.74. This value yielded 62.1 % sensitivity and 88.2 % specificity for determination of locoregional invasive tumors. From this result, the corrected 3D-IRA was used as a factor for multivariate logistic analysis.Fig. 4ROC curves of the 3D-IRA and the corrected 3D-IRA for diagnosis of locoregional invasive tumor

Table [3](#Tab3){ref-type="table"} shows the correlation between locoregional invasiveness and four clinical factors, including gender, clinical tumor size, internal opacity, and corrected 3D-IRA by multivariate logistic regression analysis. Among these four factors, only the corrected 3D-IRA was significantly correlated with locoregional invasive tumors (*p* = 0.003). For gender, clinical tumor size, and solid vs. subsolid tumors, no significant differences were observed (*p* = 0.950, *p* = 0.057, and *p* = 0.456, respectively).Table 3Multivariate logistic analysis for locoregional invasive tumorFactorsOR (95 % CI)*p*-valueMale as compared to female0.960 (0.267--3.456)0.950Clinical size1.094 (0.997--1.200)0.057Subsolid as compared with solid1.748 (0.402--7.598)0.456Corrected 3D-IRA0.733 (0.596--0.901)0.0033D-IRA, three-dimensional iodine related attenuation; CI, confidence interval; OR, odds ratio; cSize, clinical size of tumor on CT

Discussion {#Sec8}
==========

This study was designed to assess the role of enhanced DE-CT for small-sized NSCLC resected surgically and confirmed histopathologically. We researched the following two points: 1) Is the 3D-IRA associated with the differentiation grade, even in NSCLCs ≤ 3 cm in diameter? 2) Are the 3D-IRAs correlated with their invasiveness? This study revealed that the 3D-IRA was significantly correlated with differentiation grade. High-grade NSCLCs tended to show low contrast enhancement. In addition, only the corrected 3D-IRA was significantly correlated with locoregional invasiveness among four independent variables (gender, size, internal characteristics on CT, and corrected 3D-IRA) according to multivariate logistic regression analysis. Consequently, the present results demonstrated that contrast-enhanced DE-CT could diagnose malignant potential as well as fluorodeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT).

The 3D-IRA and the corrected 3D-IRA of G3 NSCLCs were lower than those of G1 and G2 tumors. This result corresponds well with that of our previous study, which reported that G3 tumors showed significantly lower enhancement than G1 and G2 tumors \[[@CR15]\]. This investigation suggested this occurred primarily due to intratumoral necrosis and fibrosis, which are closely correlated with invasiveness and prognosis of NSCLCs. In the present study, the frequency of locoregional invasive tumors in G3 tumors was higher than that in G1 and G2 tumors.

Therefore, we investigated the correlation between the 3D-IRA and degree of locoregional invasion in primary lesions. As we expected, according to univariate logistic regression analysis, the 3D-IRA, corrected 3D-IRA, pathological tumor size, and differentiation grade were significantly correlated with locoregional invasiveness. Furthermore, by multivariate logistic analysis, only the corrected 3D-IRA was significantly correlated with locoregional invasiveness among the clinical independent variables that were preoperatively obtainable. Thus, the 3D-IRA may be useful for selecting a therapeutic strategy, such as limited resection to preserve pulmonary function. Wedge resection or segmentectomy for small primary lung cancers are currently recommended for non-invasive tumors \[[@CR22]\]. However, for small-sized lung tumors, it is sometimes difficult for transbronchial lung biopsy and CT-guided transcutaneous needle biopsy to determine the differentiation grade. An intraoperative diagnosis based on frozen sections and needle biopsies is also known to have limitations due to the potential risks of physical complications, false-negative results, and the implantation of cancer cells \[[@CR23]--[@CR25]\].

According to our univariate logistic regression analysis, both the 3D-IRA and corrected 3D-IRA that is the values were corrected by body weight and concentration of contrast materials, were significantly correlated with tumor invasiveness. Thus, we investigated which value was better correlated with invasiveness by ROC analysis. As a result, the corrected values showed a higher AUC than the raw ones, although no significant difference was observed. Therefore, we used the corrected values for multivariate logistic regression analysis.

PET/CT is useful for estimating the malignancy and invasiveness of lung tumors. The maximum standardized uptake value (SUVmax) has been commonly used to evaluate the invasiveness and prognosis of NSCLC. We believe that the 3D-IRA measured by DE-CT has three advantages over SUVmax on PET/CT for evaluation of lung cancer. First, 3D-IRA can be measured not only in large-sized but also small-sized tumors, as revealed in the present study. The lesion size is significantly associated with FDG uptake \[[@CR26]--[@CR28]\]. In particular, lesions ≤ 2 cm tended to have negative PET findings. Second, this was not influenced by respiratory variation because high-speed dual source CT can evaluate the whole lung in several seconds. Third, CT is less expensive than PET/CT. A previous study revealed that the SUVmax was negatively correlated with 3D-IRA \[[@CR15]\]. Further investigation of the comparison with PET/CT is required.

This retrospective study has several limitations. First, we excluded non-solid type tumors from our study cohort, because it was difficult to measure 3D-IRA automatically using software. This represents a selection bias, as non-solid type lung adenocarcinoma is usually non-invasive \[[@CR19], [@CR29], [@CR30]\]. Second, we could not evaluate differences between adenocarcinomas and squamous cell carcinomas because the number of squamous cell carcinoma cases was relatively small. Previous FDG-PET/CT studies demonstrate that SUVs of squamous cell carcinomas are higher than those of adenocarcinomas \[[@CR20], [@CR31], [@CR32]\]. Third, since the number of patients with lymph node metastasis was relatively small, we could not evaluate the correlation with the 3D-IRA of small-sized NSCLCs. Finally, the radiation dose on contrast enhanced CT was not compared between DE-CT and conventional single energy CT. However, the recent study of Uhrig et al. demonstrated that abdominal DE-CT is feasible without increasing radiation dose or deteriorating image quality, even compared to single energy CT \[[@CR33]\].

Conclusions {#Sec9}
===========

The 3D-IRA of small-sized NSCLCs measured by DE-CT was significantly associated with differentiation grade and invasiveness. Primary lung cancers with lower 3D-IRA tended to have a high grade and be more invasive.
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